Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …

Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …

Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major …